Crossmark

Unfavorable immunotherapy plus tyrosine kinase inhibition outcome of metastatic renal cell carcinoma after radical nephrectomy with increased ADAM9 expression

Crossref DOI link: https://doi.org/10.1007/s00251-022-01292-3

Published Online: 2022-12-14

Published Print: 2023-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xu, Xianglai https://orcid.org/0000-0001-7433-8694
Wang, Ying

Chen, Zhaoyi

Zhu, Yanjun

Wang, Jiajun

Guo, Jianming
Funding

Funding for this research was provided by:

National Natural Science Foundation of China (81700660)

National Natural Science Foundation of China (81902898)

National Natural Science Foundation of China (81772696)

National Natural Science Foundation of China (81974393)

Experimental Animal Project of Shanghai Science and Technology Commission (19140905200)

Shanghai Sailing Program (19YF1407900)
License Information

Text and Data Mining valid from 2022-12-14

Version of Record valid from 2022-12-14
More Information

Article History

Received: 27 October 2022

Accepted: 5 December 2022

First Online: 14 December 2022

Declarations

:

: The study followed the Declaration of Helsinki and was approved by the Clinical Research Ethics Committee of Zhongshan Hospital, Fudan University (B2021-119). Informed consent was obtained from each participant.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below